NCT02748707 2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2 Unknown
Clinical Trials
7 trialsNCT01470716 2022-04-06
Neoadjuvant Erlotinib for Operable Stage II or IIIA NSCLC With EGFR Mutations
National Cancer Center, Korea
Phase 2 Unknown
NCT03126799 2022-04-06
AvaTa
National Cancer Center, Korea
Phase 2 Unknown
NCT01608841 2015-02-18
The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib
Taipei Veterans General Hospital, Taiwan
Phase 2 Unknown
NCT00636883 2014-01-22
GEMOX-T
National Guard Health Affairs
Phase 2 Terminated
NCT00620269 2011-11-07
Induction Chemotherapy Followed by CCRT According to EGFR Mutation Status in NSCLC III
National Cancer Center, Korea
Phase 2 Unknown
NCT00784667 2010-11-30
Dux
Austin Health
Phase 2 Unknown